For postmenopausal women
with a recent osteoporotic fracture:
help Reduce the Risk of Fractures1

TYMLOS, an anabolic agent for postmenopausal osteoporosis, demonstrated1,2:

  • 86% relative risk reduction (RRR) in new vertebral fractures vs placebo (P<0.0001) and 3.6% absolute risk reduction (ARR) at 18 months1
  • 43% RRR in nonvertebral fractures vs placebo (P=0.049) and 2.0% ARR at
    19 months1*

Data included 18 months of treatment plus 1 month without treatment; P value
based on the log-rank test.1

See how TYMLOS affected the incidence of new vertebral fractures, nonvertebral fractures, and BMD

Learn about efficacy results that were maintained with sequential therapy

Watch the abaloparatide mechanism of action video

References: 1. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 2. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.   All rights reserved.    12/18.   TYM-US-02038

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.
All rights reserved. 12/18.
TYM-US-02038

Back to Top